Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 3.01B +60.6% |
| Revenue (ttm) | 463.98M +76.1% |
| Net Income | 28.52M |
| EPS | 0.22 |
| Shares Out | 125.69M |
| PE Ratio | 111.27 |
| Forward PE | 34.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,522,061 |
| Open | 23.75 |
| Previous Close | 23.78 |
| Day's Range | 23.21 - 24.07 |
| 52-Week Range | 15.13 - 31.77 |
| Beta | 1.53 |
| Analysts | Buy |
| Price Target | 36.88 (+53.86%) |
| Earnings Date | Aug 5, 2026 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Bio... [Read more]
Financial Performance
In 2025, Arcutis Biotherapeutics's revenue was $376.07 million, an increase of 91.34% compared to the previous year's $196.54 million. Losses were -$16.14 million, -88.47% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price target is $36.88, which is an increase of 53.86% from the latest price.
News
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins Oruka from Arcutis Biotherapeutics (ARQT), where he served as execut...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $38 from $34 and keeps an Overweight rating on the shares.
Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho
Mizuho raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $36 from $35 and keeps an Outperform rating on the shares.
Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim
Guggenheim raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $38 from $35 and keeps a Buy rating on the shares. The firm increased estimates for Zoryve following the…
Arcutis Biotherapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw 59% year-over-year revenue growth, driven by strong ZORYVE demand and new patient access initiatives. Full-year guidance was raised to $525–$540 million, with continued growth expected from commercial expansion and new indications.
Arcutis Biotherapeutics Earnings release: Q2 2026
Arcutis Biotherapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Arcutis Biotherapeutics Quarterly report: Q2 2026
Arcutis Biotherapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Arcutis Biotherapeutics Slides: Q2 2026
Arcutis Biotherapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Arcutis Biotherapeutics reports Q2 EPS 11c, consensus 5c
Reports Q2 revenue $129.86M, consensus $118.85M. “Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three i...
Arcutis Biotherapeutics raises FY26 revenue view to $525M-$540M from $480M-$495M
Consensus $500.09M. The company said, “The Company raised net product sales guidance for the full year 2026 from $480 million-$495 million to $525 million-$540 million.”
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Comp...
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
Arcutis Biotherapeutics (ARQT) announced that Christopher Peetz has been appointed to the Arcutis board of directors effective July 15. Peetz currently serves as a co-founder and chief executive offic...
Arcutis Expands Board of Directors with Appointment of Chris Peetz
WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in i...
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
Arcutis Biotherapeutics (ARQT) announced that the FDA has accepted its supplemental new drug application, or sNDA, for Zoryve cream 0.05% to expand the indication for the topical treatment of mild…
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-...
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individua...
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
Arcutis Biotherapeutics (ARQT) announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application to expand the indication for ZORYVE cream 0.3% for the topical tr...
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use...
Arcutis Biotherapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Cash flow positivity enables reinvestment in ZORYVE growth and R&D, with strong sales and multiple regulatory catalysts ahead. Market access is expanding, especially in Medicare, and nonsteroidal adoption is accelerating, positioning ZORYVE as a standard of care in key indications.
Arcutis Biotherapeutics Transcript: AGM 2026
The meeting confirmed quorum and proceeded with the election of three directors, ratification of the auditor, and approval of executive compensation. All proposals passed, with final results to be filed with the SEC.
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in Miami.
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arcutis Biotherapeutics (ARQT) to $34 from $35 and keeps an Overweight rating on the shares.